- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05565378
이전에 치료받지 않은 진행성/전이성 비소세포폐암 환자를 대상으로 한 새로운 면역요법 조합의 2상 플랫폼 연구
이전에 치료받지 않은 국소 진행성/전이성 프로그램화된 사멸 리간드 1-선택 비소세포폐암 환자의 새로운 면역요법 조합을 평가하기 위해 마스터 프로토콜을 활용하는 2상, 무작위, 공개 라벨, 플랫폼 연구
This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] >= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.
연구 개요
상태
정황
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Athens, 그리스, 11528
- GSK Investigational Site
-
Pylaia Thessaloniki, 그리스, 57001
- GSK Investigational Site
-
Thessaloniki, 그리스, 54645
- GSK Investigational Site
-
-
Attica
-
Athens, Attica, 그리스, 115 27
- GSK Investigational Site
-
Chaïdári, Attica, 그리스, 124 62
- GSK Investigational Site
-
-
Central Macedonia
-
Thessaloniki, Central Macedonia, 그리스, 570 10
- GSK Investigational Site
-
-
Thessaly
-
Larissa, Thessaly, 그리스, 411 10
- GSK Investigational Site
-
-
-
-
-
Cape Town, 남아프리카, 7570
- GSK Investigational Site
-
Parktown, 남아프리카, 2193
- GSK Investigational Site
-
-
-
-
-
Enschede, 네덜란드, 7512 KZ
- GSK Investigational Site
-
Groningen, 네덜란드, 9728 NZ
- GSK Investigational Site
-
Leeuwarden, 네덜란드, 8934 AD
- GSK Investigational Site
-
Utrecht, 네덜란드, 3543 AZ
- GSK Investigational Site
-
-
-
-
-
Incheon, 대한민국, 21565
- GSK Investigational Site
-
Seoul, 대한민국, 03080
- GSK Investigational Site
-
Seoul, 대한민국, 03722
- GSK Investigational Site
-
Suwon Gyeonggi-do, 대한민국, 442-723
- GSK Investigational Site
-
-
-
-
-
Berlin, 독일, 13125
- GSK Investigational Site
-
Heidelberg, 독일, 69126
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, 독일, 45147
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Großhansdorf, Schleswig-Holstein, 독일, 22927
- GSK Investigational Site
-
-
Thuringia
-
Jena, Thuringia, 독일, 07747
- GSK Investigational Site
-
-
-
-
-
Guadajalara, 멕시코, 44280
- GSK Investigational Site
-
San Luis Potosí City, 멕시코, 78209
- GSK Investigational Site
-
-
-
-
Florida
-
Plantation, Florida, 미국, 33322-5426
- GSK Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87131
- GSK Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, 미국, 37404
- GSK Investigational Site
-
-
West Virginia
-
Morgantown, West Virginia, 미국, 26506
- GSK Investigational Site
-
-
-
-
-
Wilrijk, 벨기에, 2650
- GSK Investigational Site
-
-
-
-
-
Barretos, 브라질, 14784-400
- GSK Investigational Site
-
Porto Alegre, 브라질, 90610-000
- GSK Investigational Site
-
São Paulo, 브라질, 01246-000
- GSK Investigational Site
-
Vitória, 브라질, 29043-260
- GSK Investigational Site
-
-
-
-
-
Badajoz, 스페인, 06080
- GSK Investigational Site
-
Barcelona, 스페인, 08035
- GSK Investigational Site
-
Las Palmas de Gran Canar, 스페인, 35016
- GSK Investigational Site
-
Madrid, 스페인, 28041
- GSK Investigational Site
-
Madrid, 스페인, 28046
- GSK Investigational Site
-
Madrid, 스페인, 28027
- GSK Investigational Site
-
Málaga, 스페인, 29010
- GSK Investigational Site
-
PamplonaNavarra, 스페인, 28027
- GSK Investigational Site
-
Valencia, 스페인, 46026
- GSK Investigational Site
-
Valencia, 스페인, 46009
- GSK Investigational Site
-
-
Barcelona
-
Badalona, Barcelona, 스페인, 08916
- GSK Investigational Site
-
L'Hospitalet de Llobregat, Barcelona, 스페인, 08907
- GSK Investigational Site
-
-
-
-
-
Abu Dhabi, 아랍 에미리트
- GSK Investigational Site
-
Abu Dhabi, 아랍 에미리트, 51900
- GSK Investigational Site
-
-
-
-
-
Buenos Aires, 아르헨티나, C1426ABP
- GSK Investigational Site
-
Cipoletti Rio Negro, 아르헨티나, R8324CVE
- GSK Investigational Site
-
Ciudad Autonoma de Buenos Aire, 아르헨티나, C1414DRK
- GSK Investigational Site
-
Ciudad Autonoma de Buenos Aire, 아르헨티나, C1426AGE
- GSK Investigational Site
-
Florida, 아르헨티나, 1602
- GSK Investigational Site
-
Mar del Plata, 아르헨티나, 7600
- GSK Investigational Site
-
San Juan, 아르헨티나, J5402DIL
- GSK Investigational Site
-
Santa Fe, 아르헨티나, 3000
- GSK Investigational Site
-
-
-
-
-
Middlesbrough, 영국, TS4 3BW
- GSK Investigational Site
-
Wolverhampton, 영국, WV10 0QP
- GSK Investigational Site
-
-
Middlesex
-
Northwood, Middlesex, 영국, HA6 2RN
- GSK Investigational Site
-
-
-
-
-
Avellino, 이탈리아, 83100
- GSK Investigational Site
-
Bergamo, 이탈리아, 24125
- GSK Investigational Site
-
Pisa, 이탈리아, 57124
- GSK Investigational Site
-
Verona, 이탈리아, 37045
- GSK Investigational Site
-
-
GE
-
Genova, GE, 이탈리아, 16132
- GSK Investigational Site
-
-
-
-
-
Chiba, 일본, 277-8577
- GSK Investigational Site
-
Fukuoka, 일본, 812-8582
- GSK Investigational Site
-
Hyōgo, 일본, 673-8558
- GSK Investigational Site
-
Kanagawa, 일본, 241-8515
- GSK Investigational Site
-
Osaka, 일본, 590-0197
- GSK Investigational Site
-
Saitama, 일본, 350-1298
- GSK Investigational Site
-
-
-
-
-
Bangkok, 태국, 10210
- GSK Investigational Site
-
Chiang Mai, 태국, 50200
- GSK Investigational Site
-
Kho Hong Hat Yai, 태국, 90110
- GSK Investigational Site
-
Khon Kaen, 태국, 40002
- GSK Investigational Site
-
Pathum Thani, 태국, 12120
- GSK Investigational Site
-
-
-
-
-
Ankara, 터키 (Türkiye), 06800
- GSK Investigational Site
-
Ankara, 터키 (Türkiye), 06680
- GSK Investigational Site
-
Antalya, 터키 (Türkiye), 07070
- GSK Investigational Site
-
Istanbul, 터키 (Türkiye), 34214
- GSK Investigational Site
-
-
Atakum
-
Samsun, Atakum, 터키 (Türkiye), 55200
- GSK Investigational Site
-
-
-
-
-
Guimarães, 포르투갈, 4835-044
- GSK Investigational Site
-
Lisbon, 포르투갈, 1500-650
- GSK Investigational Site
-
Lisbon, 포르투갈, 1998-018
- GSK Investigational Site
-
Porto, 포르투갈, 4200-072
- GSK Investigational Site
-
Vila Nova de Gaia, 포르투갈, 4434-502
- GSK Investigational Site
-
-
-
-
-
Lublin, 폴란드, 20-954
- GSK Investigational Site
-
Prabuty, 폴란드, 82-550
- GSK Investigational Site
-
Siedlce, 폴란드, 08-110
- GSK Investigational Site
-
-
-
-
-
Bordeaux, 프랑스, 33076
- GSK Investigational Site
-
Caen, 프랑스, 14033
- GSK Investigational Site
-
Marseille, 프랑스, 13009
- GSK Investigational Site
-
Quimper, 프랑스, 29107
- GSK Investigational Site
-
Strasbourg, 프랑스, 67091
- GSK Investigational Site
-
-
-
-
-
Oulu, 핀란드, 90220
- GSK Investigational Site
-
Tampere, 핀란드, 33520
- GSK Investigational Site
-
Turku, 핀란드, 20520
- GSK Investigational Site
-
Vaasa, 핀란드, 65130
- GSK Investigational Site
-
-
-
-
-
Budapest, 헝가리, H-1121
- GSK Investigational Site
-
Gyöngyös, 헝가리, 3200
- GSK Investigational Site
-
Tatabánya, 헝가리, 2800
- GSK Investigational Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or non squamous)
- No prior systemic therapy for their locally advanced or metastatic NSCLC
- Provides a fresh tumor tissue sample or archival sample collected within 2 years prior to screening
- PD-L1-high (TC/TPS >= 50%) tumor
- Measurable disease based on RECIST 1.1, as determined by the investigator
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Adequate Baseline organ function
- Female participants of childbearing potential must use adequate contraception
Exclusion Criteria:
- Has NSCLC with a tumor that harbors any of the following molecular alterations: EGFR and /or ALK translocations mutations that are sensitive to available targeted inhibitor therapy, Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first-line treatment of locally advanced or metastatic NSCLC.
- Had major surgery within 4 weeks or lung radiation of >30 Gy therapy within 6 months prior to the first dose of study intervention
- Received prior therapy with any immune checkpoint inhibitors
- Never smoked, defined as smoking <100 tobacco cigarettes in a lifetime
- Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years (clinical exceptions apply as per protocol)
- Symptomatic, untreated, or actively progressing, brain metastases or any leptomeningeal disease (regardless of symptomatology, treatment status, or stability)
- Autoimmune disease or syndrome that required systemic treatment within the past 2 years
- Receiving systemic steroid therapy <= 3 days prior to first dose of study intervention or any form of immunosuppressive medication
- Received any live vaccine <= 30 days prior to first dose of study intervention
- Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
- History or evidence of cardiac abnormalities
- Current unstable liver or biliary disease
- Severe infection within 4 weeks prior to the first dose of study intervention
- Positive for tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or hepatitis C
- Has advanced, symptomatic, or visceral spread and is considered to be at imminent risk of life-threatening complications (including, but not limited to, massive uncontrolled effusions [e.g., pleural, pericardial, peritoneal])
- Is currently participating in or has participated in a study of an investigational therapy within 4 weeks prior to the first dose of study intervention
- Has a history of allogeneic tissue/stem cell transplant or solid organ transplant
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Pembrolizumab Monotherapy
Participants will be administered with pembrolizumab as monotherapy in a fixed dose. |
Pembrolizumab will be administered. |
|
실험적: Dostarlimab Monotherapy
Participants will be administered with dostarlimab as monotherapy in a fixed dose. |
Dostarlimab will be administered
다른 이름들:
|
|
실험적: Substudy 1A
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose A). |
Belrestotug will be administered.
다른 이름들:
Dostarlimab will be administered
다른 이름들:
|
|
실험적: Substudy 1B
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose B). |
Belrestotug will be administered.
다른 이름들:
Dostarlimab will be administered
다른 이름들:
|
|
실험적: Substudy 1C
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose C). |
Belrestotug will be administered.
다른 이름들:
Dostarlimab will be administered
다른 이름들:
|
|
실험적: Substudy 2A
Participants will be administered with dostarlimab, fixed dose belrestotug, and fixed dose nelistotug |
Belrestotug will be administered.
다른 이름들:
Nelistotug will be administered.
다른 이름들:
Dostarlimab will be administered
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
치료를받은 참가자 수가 부작용 (TEAE) 및 심각한 부작용 (SAE)
기간: 최대 228 주
|
최대 228 주
|
|
용량 수정 또는 치료 중단으로 이어지는 Teaes 또는 SAE 참가자 수
기간: 최대 228 주
|
최대 228 주
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 213824
- 2021-005115-32 (EudraCT 번호)
- GALAXIES LUNG-201 (기타 식별자: Study Identifier)
- 2023 (미국 NIH 보조금/계약)
- 2023-505057-40-00 (레지스트리 식별자: CTIS (EU))
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD 공유 기간
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD 공유 액세스 기준
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .